The growing prevalence of cardiovascular disease and cancer around the globe is primarily propelling the growth of the cell and gene therapy market. According to the World Health Organization (WHO), May 2017, around 17.9 million people died due to cardiovascular disease in 2016 globally, which accounts for 31% of all worldwide deaths. According to the same source, cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020.
North America is expected to hold the dominant position in the global cell and gene therapy market and this is attributed to the growing prevalence of neurological disorders in the region. According to the U.S. Pharmacist Journal, January 2018, annually, around 1.2 million adults are diagnosed with early symptoms of brain disorders, of which 21% are due to Alzheimer’s disease, and the total number of new cases of Parkinson’s disease and traumatic brain injuries are around 135 million in the U.S. Moreover, growing research and development activities in the field of cell and gene therapy is again fostering the growth of the market. According to the Catalyst report, in December 2018, around 289 novel cell and gene therapies were in development for a variety of diseases, of which around 111 medicines were for cancer and around 28 medicines were for cardiovascular disease.
The cell and gene therapy field is ripe with opportunities and potential. Advances in technology are ushering in a whole new era in treating disease through personalized health care. The field now stands at a crossroads as it struggles to keep up with advances in molecular biology and pharmaceutical manufacturing capacity. The field now stands at a fork in the road as it battles the relentless march of technology and what it can do to the cell and gene therapy field.
The cell and gene production programs currently in development will usher in a sea change in the way we treat our diseases.
Key Developments:
In April 2021, Bio-Rad Laboratories, Inc. a global marketer in life science research and clinical diagnostic products announced the launch of two products for the Droplet Digital PCR (ddPCR) platforms to support the development and manufacture of safe and effective cell and gene therapies.
In January 2021, Ixaka (formerly Rexgenero) Launches as an Integrated Cell and Gene Therapy Company. The Company’s shareholders have funded the business with over £40 million in financing
In April 2021, Bayer has announced that it has expanded its cell and gene capabilities through the addition of a Cell Therapy Launch Facility
In January 2020, Lonza announced the process development roadmap for cell and gene therapies
No comments:
Post a Comment